Seattle Genetics Highlights Data for Adcetris plus CHP in PTCL Patients

Seattle-Genetics-Inc..jpg

The biopharmaceutical is highlighting data it will present at the European Society for Medical Oncology Congress this weekend in Madrid.

Seattle Genetics will present data constituting an updated two-year durability analysis from a phase I trial testing its antibody drug conjugate Adcetris along with combination chemotherapy in patients with newly diagnosed, CD30 positive, peripheral T-cell lymphoma (PTCL).

In the trial patients received Adcetris coupled with what is considered standard treatment for PTCL, notably, either the CHOP chemotherapy regimen (A+CHOP), or CHP (A+CHP, CHOP minus vincristine).

Since PTCL is such a broad category, there was bound to be variations in the recruited patients, and indeed among the 26 patients:

  • Nineteen have systemtic anaplastic large cell lymphoma (sALCL)
  • Of those nineteen, sixteen have ALK-negative disease, associated with significantly poorer prognoses
  • Seven patients with other unnamed types of PTCL

So the updated findings include the following, based on a median observation time of 27.1 months and involving those receiving A+CHP:

  • Estimated 2 year progression-free survival rate is 54 percent; no progression events to report since they first reported data on this trial at the ASH meeting about ten months ago
  • Estimated 2 year overall survival rate is 80 percent
  • Common side effects, occurring in over 40 percent of patients: peripheral sensory neuropathy, nausea, fatigue, hair loss, diarrhea, shortness of breath

Seattle Genetics has already begun recruiting for a pivotal phase III randomized, double-blind, placebo-controlled trial pitting A+CHP against CHOP as front-line treatment in this patient population.

Source: Seattle Genetics

LymphomaInfo Social